文献速递糖尿病肥胖与代谢综合征

Cotadutide 对超重或肥胖合并2型糖尿病成人代谢及肝脏指标的影响:54周随机2b期研究

Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study.
PubMed 文献 · Diabetes Care · 2021-05-20

这项2b期研究纳入834例BMI≥25 kg/m²且二甲双胍控制不佳的2型糖尿病成人,随机接受Cotadutide 100/200/300 μg、安慰剂或利拉鲁肽1.8 mg治疗54周。Cotadutide显著降低HbA1c和体重,300 μg组还改善血脂、肝酶及肝纤维化指标,常见不良事件为恶心和呕吐。

要点

  • Cotadutide显著降低HbA1c和体重,300 μg组减重优于利拉鲁肽1.8 mg。
  • 300 μg组改善AST、ALT、III型胶原前肽及FIB-4、NAFLD纤维化评分。
  • 常见不良事件为恶心(35%)和呕吐(17%),随时间推移减少。

核心结论

  • Cotadutide治疗54周改善超重/肥胖合并2型糖尿病患者的血糖控制和体重。
  • 事后分析显示Cotadutide改善肝脏指标,支持其在NASH中的进一步评估。

研究设计与样本

  • 2b期随机双盲研究,834例BMI≥25 kg/m²且二甲双胍控制不佳的2型糖尿病成人。
  • 随机接受Cotadutide 100 μg(n=100)、200 μg(n=256)、300 μg(n=256)、安慰剂(n=110)或开放标签利拉鲁肽1.8 mg(n=110),皮下给药。
  • 共同主要终点为第14周HbA1c和体重变化,原随机干预持续至第54周。

主要发现

  • Cotadutide在第14周和第54周显著降低HbA1c和体重 vs 安慰剂(均P<0.001)。
  • Cotadutide 300 μg vs 安慰剂改善血脂谱、AST、ALT、III型胶原前肽、FIB-4和NAFLD纤维化评分,利拉鲁肽无此改善。
  • Cotadutide 200 μg减重与利拉鲁肽1.8 mg相似,300 μg减重优于利拉鲁肽1.8 mg。
  • 最常见不良事件为恶心(35%)和呕吐(17%),随时间推移减少。

关键数值与推荐

  • 纳入标准:BMI≥25 kg/m²,2型糖尿病,二甲双胍控制不佳,HbA1c 7.0%-10.5%(53-91 mmol/mol)。

临床怎么用

  • Cotadutide可改善超重/肥胖合并2型糖尿病患者的血糖和体重,并可能改善肝脏指标。
  • 需关注恶心和呕吐等胃肠道不良事件,但随时间推移可减轻。

局限性

  • 肝脏指标改善来自事后分析(ad hoc analyses),需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Cotadutide, a dual GLP-1 and glucagon receptor agonist, is under development for nonalcoholic steatohepatitis (NASH) and chronic kidney disease with type 2 diabetes. The effects of cotadutide on hepatic and metabolic parameters were evaluated in participants with overweight/obesity and type 2 diabetes. RESEARCH DESIGN AND METHODS: In this phase 2b study, 834 adults with BMI ≥25 kg/m2 and type 2 diabetes inadequately controlled with metformin (glycated hemoglobin A1c [HbA1c] of 7.0%-10.5% [53-91 mmol/mol]) were randomized to double-blind cotadutide 100 μg (n = 100), 200 μg (n = 256), or 300 μg (n = 256); placebo (n = 110); or open-label liraglutide 1.8 mg (n = 110)-all administered subcutaneously. Coprimary end points were changes in HbA1c and body weight at week 14. The originally randomized interventions were continued to week 54. Liver damage biomarkers and liver fibrosis algorithms were assessed. RESULTS: Cotadutide significantly decreased HbA1c and body weight at weeks 14 and 54 versus placebo (all P < 0.001). Improvements in lipid profile, AST and ALT levels, propeptide of type III collagen level, fibrosis-4 index, and nonalcoholic fatty liver disease fibrosis score were observed with cotadutide 300 μg versus placebo, but not with liraglutide. Weight loss with cotadutide 200 μg was similar to that with liraglutide 1.8 mg and greater with cotadutide 300 μg versus liraglutide 1.8 mg. The most common adverse events with cotadutide (nausea, 35%; vomiting, 17%) decreased over time. CONCLUSIONS: Cotadutide treatment for 54 weeks improved glycemic control and weight loss in participants with overweight/obesity and type 2 diabetes. Ad hoc analyses demonstrated improvements in hepatic parameters and support further evaluation of cotadutide in NASH.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Nahra R, Wang T, Gadde KM, et al. Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study. Diabetes Care. 2021. PMID: 34016612. doi:10.2337/dc20-2151

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。